Filtrar atividades
10:25 - 10:30 Abertura


10:30 - 11:45 Módulo

Módulo Genitourinário

10:30 - 10:37
Abstract 5002
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
10:37 - 10:45
Abstract 5004
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
10:45 - 10:52
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
10:52 - 11:00
Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
11:00 - 11:07
Abstract 4508
SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
11:07 - 11:15
Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
11:15 - 11:45
11:45 - 12:45 Módulo

Módulo Câncer de Pele e Sarcomas

11:45 - 11:52
Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma - CheckMate358
11:52 - 12:00
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
12:00 - 12:07
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
12:07 - 12:15
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
12:15 - 12:22
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
12:22 - 12:30
Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.
12:30 - 12:45
12:45 - 14:00 Intervalo


14:00 - 15:00 Módulo

Módulo Cabeça e pescoço/Neuro

14:00 - 14:05
Abstract 6001
Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial.
14:05 - 14:10
Abstract LBA6002
PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM).
14:10 - 14:15
Abstract 6000
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.
14:15 - 14:20
Abstract 6007
Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.
14:20 - 14:25
Abstract 6008
Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.
14:25 - 14:30
Abstract 6005
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.
14:30 - 14:37
Abstract 2008
Belzutifan treatment for von Hippel-Lindau (VHL) disease–associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.
14:37 - 14:45
Abstract LBA1
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
14:45 - 15:00
15:00 - 17:00 Módulo

Módulo Pulmão/Novas terapias

15:00 - 15:07
Abstract 2503
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
15:07 - 15:15
KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
15:15 - 15:22
OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIA NSCLC.
15:22 - 15:30
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.
non-squamous, non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L).
15:30 - 16:00
16:00 - 16:07
Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
16:07 - 16:15
Abstract 9004
TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
16:15 - 16:23
Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
16:23 - 16:30
Abstract 9006
The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in advanced
16:30 - 17:00
17:00 - 17:20 Módulo

Módulo Digital

17:00 - 17:06
Abstract 1008
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy.
Primary outcome analysis of the multicenter randomized PreCycle trial.
17:06 - 17:12
Abstract 1518
Towards improvement of oncology care through digital technology: a snapshot of Resilience Remote Patient Monitoring (RPM) system implementation across 19 hospitals in Europe
17:12 - 17:18
Abstract 1507
A Cognitive Behavioral Digital Therapeutic for Anxiety and Depression in Patients with Cancer.
A Decentralized Randomized Controlled Trial.
17:18 - 17:20
17:20 - 18:00 Módulo

Instituto Projeto Cura / Divulgação do Vencedor do 5º Prêmio Renata Thormann Procianoy

O Prêmio Renata Thormann Procianoy, iniciativa do Instituto Projeto CURA, analisa e premia, através de uma Coordenação Científica, o melhor estudo brasileiro, submetido na ASCO 2023 e, tem como objetivo prestar o reconhecimento e motivar a comunidade científica a seguir com suas investigações de excelência.
18:00 - 18:05 Encerramento


08:25 - 08:30 Abertura


08:30 - 09:30 Módulo

Módulo Ginecologia

08:30 - 08:38
An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
08:38 - 08:45
Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.
08:45 - 08:50
Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
08:50 - 08:55
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
08:55 - 09:00
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
09:00 - 09:08
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.
09:08 - 09:15
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
09:15 - 09:30
09:30 - 10:45 Módulo

Módulo Mama

09:30 - 09:35
Abstract 1006
An age-specific pooled analysis of trastuzumab deruxtecan (T DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.
09:35 - 09:40
Abstract 1007
Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
09:40 - 09:45
Abstract 1003
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).
09:45 - 09:52
LBA 500
Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.
09:52 - 10:00
Abstract 501
Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
10:00 - 10:07
LBA 1000
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
10:07 - 10:15
Abstract 503
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
10:15 - 10:45
10:45 - 11:15 Intervalo


11:15 - 11:45 Simpósio Satélite

Simpósio Satélite - Impacto do tratamento adjuvante com inibidores de CDK 4/6 em câncer de mama HR positivo HER2 negativo: novas perspectivas com resultados do estudo NATALEE

11:45 - 13:00 Módulo

Módulo Gastrointestinal

11:45 - 11:50
Abstract 4008
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).
11:50 - 11:55
Abstract 4002
Efficacy, safety and patient reported outcomes (PROs) from the phase III IMbrave050 trial of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation.
11:55 - 12:00
LBA 4005
Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: A multicenter randomized phase-II trial (NORPACT-1).
12:00 - 12:07
Abstract 3506
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.
12:07 - 12:15
Abstract 3507
Oral session Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.
12:15 - 12:20
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
12:20 - 12:25
Abstract 3505
Oral session Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial.
12:25 - 12:30
Abstract 3501
Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
12:30 - 13:00
13:00 - 13:05 Encerramento